Co-Authors
This is a "connection" page, showing publications co-authored by ROBERT ORLOWSKI and PETER F THALL.
Connection Strength
0.168
-
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019 May; 6(5):e266-e275.
Score: 0.042
-
High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma. 2019 02; 60(2):442-452.
Score: 0.040
-
Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia. 2015 Sep; 29(9):1945-8.
Score: 0.032
-
A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1453-8.
Score: 0.029
-
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 2012 May 01; 118(9):2507-15.
Score: 0.025